Head and Neck Cancer Trial, Recruiting NCT05757817 Sponsor: Institut Claudius Regaud Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT05757817
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the mouth or throat, confirmed by a tissue biopsy
  • People whose cancer is at a specific stage — it has not spread to distant parts of the body, and falls within a defined range of tumor and lymph node involvement (confirm with trial site for exact staging details)
  • People whose mouth or throat reconstruction surgery requires a specific type of tissue transplant called a free fasciocutaneous flap, as determined by an experienced cancer surgeon
  • People who are in good to very good general health, with minimal or no limitations on daily activity (WHO performance status 0–1)
  • People aged 18 or older
  • People who have no medical reasons preventing them from having surgery
  • People who are enrolled in the French social health insurance system
  • People who are able to understand the study and are willing to give written consent before any study procedures begin

Who may not be able to join:

  • People who have previously had surgery or radiation treatment to the neck or head and neck area
  • People who have previously had surgery or radiation treatment to the pelvic area
  • People who have a medical reason preventing them from receiving any form of sedation or anaesthesia
  • People who have a blood clotting disorder that cannot be treated or reversed
  • People who are unable to have a CT scan or receive the contrast dye used during CT imaging
  • People with active autoimmune conditions who are currently taking immune-suppressing medications, including steroids at doses above the equivalent of 10 mg of prednisone per day
  • People who are pregnant or breastfeeding
  • People who have another active cancer at the time of joining, or another serious medical, psychiatric, or surgical condition that is not currently under control and could affect the study
  • People who have diabetes (type 1 or type 2)
  • People with a Body Mass Index (BMI) above 30 kg/m²
  • People whose personal, family, geographic, or social circumstances would make it difficult to follow the study schedule and requirements
  • People who are under legal guardianship, court protection, or who have had their freedom restricted by an administrative or legal order

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 05 31 15 53 08

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut Claudius Regaud
Registry
ClinicalTrials.gov
Start date
8 November 2023
Est. completion
1 May 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

The occurrence of a limiting complication. Limiting complications are defined as total flap necrosis (flap failure) or donor site infection (Fournier Gangrene) within 4 weeks of the experimental procedure.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov